Multiple myeloma (MM) is a plasma cell disorder representing the second most common blood cancer (1). MM is still defined as an incurable disease, but survival has nearly doubled in latest years due to novel drugs and novel therapeutic strategies (Gozzetti et al.,2–4). Also, high-risk MM had benefited from novel therapies, although with less potency (5–8). Knowledge of the molecular mechanisms and pathogenesis of MM is behind this progress, in particular genetics of the monoclonal plasma cells and their interactions with the microenvironment (9, 10).
MM cell proliferation and apoptosis are touched by the paper entitled “Study of Tim3 regulation in multiple myeloma cell proliferation via NF-kB signal pathways” (Liu et al.). T-cell immunoglobulin and mucin domain-3 (Tim3) is a negative regulatory factor of cellular immunity (11). In this study, Liu et al. found a higher expression of Tim3 by flow cytometry in bone marrow plasma cells derived from 167 MM patients when compared with 51 healthy donors. Additionally, higher Tim3 expression level was associated with poorer prognostic factor based on International Staging System (ISS) stage III when compared to stage I and II. Mechanistically, the authors showed that cell proliferation was decreased, and apoptosis was induced via NF-kB signaling upon Tim3 knocked-down in vitro by siRNA using two MM cell lines. Furthermore, the authors observed that Tim3 knockdown used in combination with the anti-myeloma therapy bortezomib had an additive effect on apoptosis in MM cell lines. This suggests that Tim3 may be a potential therapeutic target.
Host immunity is crucial in antitumor activity. In the paper entitled “Metabolic reprogramming induces immune cell dysfunction in the tumor microenvironment of multiple myeloma”, Wu et al. review data about metabolic reprogramming in MM, which is associated with the hypoxic, acidic, and nutritionally deficient microenvironment. In particular, authors remark how these findings can negatively impact the anti-tumor activity of the immune cells, i.e. T-cell mediated tumor lysis via silencing of PTPN1, TP53I11 induced by hypoxia (12, Wegiel et al.), reduced NK activity by decreased ligand receptors RAE-1 and PVR on MM cells (13) and PD-L1 upregulation via HIF-1a (14).
Metabolic abnormalities are important in cancer, age, obesity can be cancer-promoting factors and can affect also disease responsiveness and progression. Lazaris et al. in the paper “The lipoprotein transport system in the pathogenesis of multiple myeloma: advances and challenges,” review the role of bone marrow adipocytes to support growth and proliferation of MM plasma cells and bone remodeling (15, 16). The deregulation of the lipoprotein system seems to correlate with MM development together with obesity. Interestingly, different studies looked at serum lipid assessment in MM patients during treatment and one found higher APOA1 (the major apolipoprotein of high-density lipoprotein HDL) related to better survival (17–19).
Methylation has been reported to be present in MM (20), although hypomethylating agents are not very much used in clinical practice. The paper “KDM2A targets PFKB3 for ubiquitylation to inhibit the proliferation and angiogenesis of multiple myeloma cells” by Liu et al. showed that the lysine demethylase KDM2A acts not only as an epigenetic regulator in cancer but also as an inhibitor of MM plasma cells proliferation and angiogenesis through ubiquitination of PFKB3, a crucial enzyme in glycolysis (21, 22). Moreover, IL-32 and the vascular endothelial growth factor (VEGF), direct key players in promoting angiogenesis, were measured and found increased in knockdown KDM2A MM cells. These findings suggest KDM2A ubiquitination of PFKB3 as a possible therapeutic target in myeloma.
Extramedullary MM (EMM) represents an unmet clinical need in daily practice (23–25). Even though new drugs increased the percentage of responses in this field, the prognosis is still poor. Much remains unknown on the molecular basis of EMM. In the last article, “Intratumor heterogeneity of MIF expression correlates with extramedullary involvement in myeloma,” Xu et al. highlight the role of MIF (macrophage migration inhibitory factor) expression in the development of EMM. In particular, authors found low levels of MIF expression in extramedullary biopsies of 17 patients compared to intramedullary biopsies. MIF high expression induced high proliferation of MM cells in in vivo mouse models, suggesting a role for MIF in EMM.
Altogether these studies highlight the different molecular mechanisms of MM development and aggressiveness and suggest a possible new target for MM therapy.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Acknowledgments
The Topic Editors thank all the contributors for submitting their work to this Research Topic, to the Review Editors and external Reviewers who participated in the review process, and to the Editorial and Production teams of Frontiers for their support through the various stages of the publication process.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
SiegelRLMillerKDFuchsHEJemalA. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
2
MohtyMTerposEMateosMVCavoMLejnieceSBeksacMet al. EMMOS Investigators. Multiple Myeloma Treatment in Real-World Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clin Lymphoma Myeloma Leuk (2018) 18:e401–19. doi: 10.1016/j.clml.2018.06.018
3
KumarSKRajkumarSVDispenzieriALacyMQHaymanSRBuadiFKet al. Improved Survival in Multiple Myeloma and the Impact of Novel Therapies. Blood (2008) 111:2516–20. doi: 10.1182/blood-2007-10-116129
4
OcioEMRichardsonPGRajkumarSVPalumboAMateosMVOrlowskiRet al. New Drugs and Novel Mechanisms of Action in Multiple Myeloma 2013: A Report From the International Myeloma Working Group (IMWG). Leukemia (2014) 28:525–42. doi: 10.1038/leu.2013.350
5
GozzettiACeraseALottiFRossiDPalumboAPetrucciMTet al. Extramedullary Intracranial Localization of Multiple Myeloma and Treatment With Novel Agents: A Retrospective Survey of 50 Patients. Cancer (2012) 118:1574–84. doi: 10.1002/cncr.26447
6
GozzettiACeraseA. Novel Agents in CNS Myeloma Treatment. Cent Nerv Syst Agents Med Chem (2014) 14:23–7. doi: 10.2174/1871524914999140818111514
7
CastilloJJJurczyszynABrozovaLCrusoeECzepielJDavilaJet al. IgM Myeloma: A Multicenter Retrospective Study of 134 Patients. Am J Hematol (2017) 92(8):746–51. doi: 10.1002/ajh.24753
8
JurczyszynARadochaJDavilaJFialaMAGozzettiAGrząśkoNet al. Prognostic Indicators in Primary Plasma Cell Leukaemia: A Multicentre Retrospective Study of 117 Patients. Br J Haematol (2018) 180(6):831–39. doi: 10.1111/bjh.15092
9
HideshimaTMitsiadesCTononGRichardsonPGAndersonKC. Understanding Multiple Myeloma Pathogenesis in the Bone Marrow to Identify New Therapeutic Targets. Nat Rev Cancer (2007) 7(8):585–98. doi: 10.1038/nrc2189
10
Di MarzoLDesantisVSolimandoAGRuggieriSAnneseTNicoBet al. Microenvironment Drug Resistance in Multiple Myeloma: Emerging New Players. Oncotarget (2016) 7(37):60698–711. doi: 10.18632/oncotarget.10849
11
MonneyLSabatosCAGagliaJLRyuAWaldnerHChernovaTet al. Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease. Nature (2002) 415(6871):536–41. doi: 10.1038/415536a
12
JankerLMayerRLBileckAKreutzDMaderJCUtpatelKet al. Metabolic, Anti-Apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia. Mol Cell Proteomics (2019) 18(5):936–53. doi: 10.1074/mcp.RA119.001390
13
GuillereyCNakamuraKVuckovicSHillGRSmythMJ. Immune Responses in Multiple Myeloma: Role of the Natural Immune Surveillance and Potential of Immunotherapies. Cell Mol Life Sci (2016) 73(8):1569–89. doi: 10.1007/s00018-016-2135-z
14
BensonDMBakanCEMishraAHofmeisterCCEfeberaYBecknellBet al. The PD-1/PD-L1 Axis Modulates the Natural Killer Cell Versus Multiple Myeloma Effect: A Therapeutic Target for CT-011, a Novel Monoclonal Anti–PD-1 Antibody. Blood (2010) 116(13):2286–94. doi: 10.1182/blood-2010-02-271874
15
AllegraAInnaoVGeraceDAllegraAGVaddinelliDBiancoOet al. The Adipose Organ and Multiple Myeloma: {Impact} of Adipokines on Tumor Growth and Potential Sites for Therapeutic Intervention. Eur J Intern Med (2018) 53:12–20. doi: 10.1016/j.ejim.2018.05.033
16
LiuHHeJKohSPZhongYLiuZWangZet al. Reprogrammed Marrow Adipocytes Contribute to Myeloma-Induced Bone Disease. Sci Transl Med (2019) 11:eaau9087. doi: 10.1126/scitranslmed.aau9087
17
YavasogluITombulogluMKadikoyluGDonmezACagirganSBolamanZ. Cholesterol Levels in Patients With Multiple Myeloma. Ann Hematol (2008) 87:223–8. doi: 10.1007/s00277-007-0375-6
18
LiangLLiJFuHLiuXLiuP. Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients With Multiple Myeloma. J Cancer (2019) 10:4852–9. doi: 10.7150/jca.31357
19
GozzettiAGennariLMerlottiDSalvadoriSDe PaolaVAvanzatiAet al. The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients. Calcif Tissue Int (2008) 82(4):258–62. doi: 10.1007/s00223-008-9123-8
20
HeuckCJMehtaJBhagatTGundaboluKYuYKhanSet al. Myeloma is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early During Myelomagenesis. J Immunol (2013) 190:2966–75. doi: 10.4049/jimmunol.120249
21
LuLGaoYZhangZCaoQZhangXZouJet al. Kdm2a/B Lysine Demethylases Regulate Canonical Wnt Signaling by Modulating the Stability of Nuclear Beta-Catenin. Dev Cell (2015) 33(6):660–74. doi: 10.1016/j.devcel.2015.04.006
22
MarsinASBouzinCBertrandLHueL. The Stimulation of Glycolysis by Hypoxia in Activated Monocytes Is Mediated by AMP-Activated Protein Kinase and Inducible 6-Phosphofructo-2-Kinase. J Biol Chem (2002) 277(34):30778–83. doi: 10.1074/jbc.M205213200
23
BladeJFernandez de LarreaCRosinolLCibeiraMTJimenezRPowlesR. Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. J Clin Oncol (2011) 29(28):3805–12. doi: 10.1200/JCO.2011.34.9290
24
UsmaniSZHeuckCMitchellASzymonifkaJNairBHoeringAet al. Extramedullary Disease Portends Poor Prognosis in Multiple Myeloma and Is Over-Represented in High-Risk Disease Even in the Era of Novel Agents. Haematologica (2012) 97(11):1761–7. doi: 10.3324/haematol.2012.065698
25
AviviICohenYCSuskaAShragaiTMikalaGGarderetLet al. Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. Am J Hematol (2019) 94(10):1132–40. doi: 10.1002/ajh.25579
Summary
Keywords
multiple myeloma, genetics of myeloma, extramedullary, biology, signaling
Citation
Gozzetti A, Kok CH and Li C-F (2022) Editorial: Molecular Mechanisms of Multiple Myeloma. Front. Oncol. 12:870123. doi: 10.3389/fonc.2022.870123
Received
05 February 2022
Accepted
18 February 2022
Published
10 March 2022
Volume
12 - 2022
Edited and reviewed by
Alessandro Isidori, AORMN Hospital, Italy
Updates
Copyright
© 2022 Gozzetti, Kok and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessandro Gozzetti, gozzetti@unisi.it
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.